The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium-Reference-Cited by-同舟云学术

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium

Published:2011-06 Issue:9 Volume:47 Page:1373-1379
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Vrooman Lynda M.,Neuberg Donna S.,Stevenson Kristen E.,Asselin Barbara L.,Athale Uma H.,Clavell Luis,Cole Peter D.,Kelly Kara M.,Larsen Eric C.,Laverdière Caroline,Michon Bruno,Schorin Marshall,Schwartz Cindy L.,Cohen Harvey J.,Lipshultz Steven E.,Silverman Lewis B.,Sallan Stephen E.

Funder

National Cancer Institute of the National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference43 articles.

1. Treating childhood acute lymphoblastic leukemia without cranial irradiation;Pui;N Engl J Med,2009

2. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95;Moricke;Blood,2008

3. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial;Mitchell;Br J Haematol,2005

4. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004);Veerman;Lancet Oncol,2009

5. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report;Gaynon;Leukemia,2010

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting autophagy with SAR405 alleviates doxorubicin-induced cardiotoxicity;Cell Biology and Toxicology;2023-09-28

2. A prospective study to evaluate the efficacy and safety of vitamin E and levocarnitine prophylaxis against doxorubicin-induced cardiotoxicity in adult breast cancer patients;Journal of Oncology Pharmacy Practice;2023-05-08

3. Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity;Journal of Oncology Pharmacy Practice;2022-12-25

4. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines;Cochrane Database Systematic Reviews;2022-10-27

5. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients;Expert Opinion on Pharmacotherapy;2022-09-14